A Phase 2 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 2, and was the 7th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
This study's enrollment of 27 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca: 3 open now, 7 under way, 2 of them phase 3. Of 26 finished, 18 (69%) have results posted.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 11th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 2, and was the 6th registered.
AstraZeneca’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 35 in Hemoglobinuria, Paroxysmal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of eculizumab were conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
Drug: Eculizumab
Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
Also known as: Soliris
Change From Baseline in Lactate Dehydrogenase
Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Change From Baseline in FACIT-Fatigue Scale Total Score
The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Change From Baseline in PNH Red Blood Cell (RBC) Count
Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Change From Baseline in Number of Units of Packed RBCs Transfused
Baseline is defined as the number of units transfused in 3 months prior to baseline
Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
Change From Baseline in Plasma Free Hemoglobin
Time frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study)
| Milestone | Eculizumab |
|---|---|
| Started | 27 |
| Completed | 26 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Units/Liter | Eculizumab |
|---|---|
| Change From Baseline in Lactate Dehydrogenase | -15.9 ± 1.20 |
The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
| units on a scale | Eculizumab |
|---|---|
| Change From Baseline in FACIT-Fatigue Scale Total Score | 8.0 ± 1.95 |
| cellsx10^12/L | Eculizumab |
|---|---|
| Change From Baseline in PNH Red Blood Cell (RBC) Count | 0.51 ± 0.129 |
Baseline is defined as the number of units transfused in 3 months prior to baseline
| units | Eculizumab |
|---|---|
| Change From Baseline in Number of Units of Packed RBCs Transfused | -3.5 ± 1.43 |
| mg/dL | Eculizumab |
|---|---|
| Change From Baseline in Plasma Free Hemoglobin | -13.5 ± 8.55 |
Collected over From baseline (after first dose) to end of study (1 year).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 0/27 (0%) | 12/27 (44.4%) | 26/27 (96.3%) |
| Event | Eculizumab |
|---|---|
| PneumoniaInfections and infestations | 4/27 |
| AnaemiaBlood and lymphatic system disorders | 2/27 |
| PyrexiaGeneral disorders | 2/27 |
| HaemolysisBlood and lymphatic system disorders | 1/27 |
| ColitisGastrointestinal disorders | 1/27 |
| CholelithiasisHepatobiliary disorders | 1/27 |
| Jaundice cholestaticHepatobiliary disorders | 1/27 |
| BronchitisInfections and infestations | 1/27 |
| CellulitisInfections and infestations | 1/27 |
| Gastroenteritis viralInfections and infestations | 1/27 |
| Event | Eculizumab |
|---|---|
| NasopharyngitisInfections and infestations | 21/27 |
| Upper respiratory tract infectionInfections and infestations | 6/27 |
| Blood alkaline phosphatase increasedInvestigations | 6/27 |
| HeadacheNervous system disorders | 6/27 |
| GastroenteritisInfections and infestations | 5/27 |
| DiarrhoeaGastrointestinal disorders | 4/27 |
| PyrexiaGeneral disorders | 4/27 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 4/27 |
| AnaemiaBlood and lymphatic system disorders | 3/27 |
| Conjunctival haemorrhageEye disorders | 3/27 |
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 48.3 ± 12.35 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 14 |
| Male | 13 |
| Race/Ethnicity, Customized(Participants) | Eculizumab |
|---|---|
| Japanese | 27 |
| Region of Enrollment(Participants) | Eculizumab |
|---|---|
| Japan | 27 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2019, 8 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →